Analyst firms · UBS · BIIB
UBS BIIB price target and rating history
Biogen Inc. (BIIB) · Health Care
UBS rates Biogen Inc. (BIIB) Buy with a $225 price target, as of its latest action on Apr 22, 2026. It has published 5 rating actions on BIIB since September 2021, including 1 upgrade and 1 downgrade. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. UBS's $225 is 3% below that.
- Current rating
- Buy
- Price target
- $225
- Median target, all firms
- $231.50
- Actions on BIIB
- 5
UBS price target on BIIB
Every UBS rating on BIIB
- Apr 22, 2026
- Jan 7, 2026
- Jan 24, 2024
- Jul 24, 2023
- Sep 16, 2021
How other firms rate BIIB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Buy | $280 | Oct 29, 2026 |
| Wolfe Research | Outperform | $300 | Aug 13, 2026 |
| Truist Securities | Buy | $235 | Jul 13, 2026 |
| Needham | Buy | $255 | Jun 8, 2026 |
| Evercore ISI | Outperform | May 15, 2026 | |
| UBS | Buy | $225 | Apr 22, 2026 |
| Wells Fargo | Overweight | $250 | Apr 20, 2026 |
| Piper Sandler | Overweight | $214 | Apr 14, 2026 |
| Barclays | Equal Weight | $185 | Feb 20, 2026 |
| H.C. Wainwright | Buy | $228 | Feb 9, 2026 |
| HSBC | Reduce | $143 | Dec 10, 2025 |
Questions about UBS and BIIB
- What is UBS's price target for BIIB?
- UBS's latest stated price target for Biogen Inc. (BIIB) is $225, from its action on Apr 22, 2026.
- What is UBS's rating on BIIB?
- UBS rates BIIB Buy, a bullish rating, as of Apr 22, 2026.
- When did UBS last change its view on BIIB?
- On Apr 22, 2026, UBS upgrades to Buy from Neutral, price target $225.
- How does UBS's BIIB target compare with other analysts?
- Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. UBS's $225 is 3% below that.
More BIIB rating histories
- Argus Research3
- Wolfe Research3
- Needham9
- Wells Fargo5
- Piper Sandler4
- Barclays4
- HSBC3
- Stifel5
- Jefferies3
- BMO Capital Markets4
- BofA Securities3
- Morgan Stanley8
- Raymond James3
- Robert W. Baird3
- Mizuho3
- RBC Capital Markets7
- Oppenheimer3
All UBS ratingsBIIB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.